Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma × imgatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 2 Neoplasms 2 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 55 Carboplatin 48 Paclitaxel 42 pembrolizumab 41 Gemcitabine 28 Pemetrexed 22 Radiotherapy 21 Magnetic Resonance Spectroscopy 20 Radiotherapy, Intensity-Modulated 18 Docetaxel 17 Cetuximab 17 Specimen Handling 16 Nivolumab 16 Fluorouracil 16 Cyclophosphamide 14 durvalumab 13 Bevacizumab 12 Radiation 11 Sorafenib 10 Platinum 10 130-nm albumin-bound paclitaxel 10 1,2-diaminocyclohexaneplatinum II citrate 10 osimertinib 9 Sunitinib 8 Oxaliplatin 8 Irinotecan 8 Everolimus 8 Drug Therapy 8 Capecitabine 8 atezolizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04985825 2022-09-13

I-PACE

Centessa Pharmaceuticals plc

Phase 2 Withdrawn

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡